<DOC>
	<DOC>NCT01672996</DOC>
	<brief_summary>To optimize both the Ioforminol concentration and dosage(s) for CECT of the abdomen. To evaluate the safety and tolerability of low concentration Ioforminol Injections. Study recruits healthy volunteers.</brief_summary>
	<brief_title>Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy males or females between 18 and 50 years of age. The subject has a maximum abdominal circumference of 120 cm or less. The subject has known Grade 3 or 4 allergic reaction/hypersensitivity to either iodine or any iodinatedbased contrast agent or with history of multiple allergies (i.e., foods, pets, medications, etc). The subject has chronic renal insufficiency (estimated glomerular filtration rate [eGFR] &lt;60 mg/dL) as measured at the screening visit. The subject is pregnant or breastfeeding. The subject has suspicion or diagnosis of hyperthyroidism or autonomously functioning thyroid nodule confirmed by T3, T4, and/or thyroidstimulating hormone. The subject has severe liver or hematologic diseases (sickle cell disease or multiple myeloma), or immunodeficiency. The subject is taking metformin (e.g., GlucophageÂ®) therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Use in Abdominal</keyword>
	<keyword>Contrast Enhanced</keyword>
	<keyword>Computed Tomography</keyword>
	<keyword>Optimize concentration</keyword>
	<keyword>dosage of Ioforminol Injection</keyword>
</DOC>